Rozerem was approved by the U.S. Food and Drug Administration (FDA) in July 2005 for use as detailed above, and became the first prescription medication indicated for insomnia which is not designated as a controlled substance by the U.S. Drug Enforcement Administration (DEA).

Rozerem has quickly become popular mainly because it has not been shown to cause dependence, and has shown no potential for abuse. Additionally, the withdrawal and rebound insomnia that is typical with some sleep medications is not present in Rozerem.

Rozerem in the news

New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia - MORE